Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Operations (2016 - 2025)

Tg Therapeutics has reported Cash from Operations over the past 10 years, most recently at 19660000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 19660000.0 for Q4 2025, up 176.67% from a year ago — trailing twelve months through Dec 2025 was 24772000.0 (up 38.86% YoY), and the annual figure for FY2025 was 24772000.0, up 38.86%.
  • Cash from Operations for Q4 2025 was 19660000.0 at Tg Therapeutics, up from 23153000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for TGTX hit a ceiling of 83704000.0 in Q3 2023 and a floor of 86909000.0 in Q4 2021.
  • Median Cash from Operations over the past 5 years was 27178000.0 (2024), compared with a mean of 28425300.0.
  • Biggest five-year swings in Cash from Operations: surged 342.66% in 2023 and later tumbled 249.88% in 2025.
  • Tg Therapeutics' Cash from Operations stood at 86909000.0 in 2021, then surged by 72.53% to 23870000.0 in 2022, then soared by 44.66% to 13210000.0 in 2023, then plummeted by 94.1% to 25641000.0 in 2024, then surged by 176.67% to 19660000.0 in 2025.
  • The last three reported values for Cash from Operations were 19660000.0 (Q4 2025), 23153000.0 (Q3 2025), and 7436000.0 (Q2 2025) per Business Quant data.